
BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Continues to be a leader in membranes

11 July 2011 | News



RANK 16

Revenue ₹84.17 Crore

Advanced Microdevices


MD: Mr Nalini Kant Gupta

Business: Production of microporous membranes and separation products

Start-up Year: 1976

Address: No.20-21, Industrial Area, Ambala Cantonment, Haryana-33006
Tel: +91-171-2699290/471
Fax: +91-171-2699221/008
Website: www.mdimembrane.com

A new 85,000 sq ft state-of-the-art GMP facility has been set up recently by the company at a cost of over ₹20 crore



Advanced Microdevices (MDI) registered a growth of over 21 percent in 2010-11 with an estimated revenue of ₹68 crore in 2010-11 as compared to ₹56 crore in 2009-10.

A new 85,000 sq ft state-of-the-art GMP facility has been set up recently by the company at a cost of over ₹20 crore. This facility includes a 10,000 sq ft Class 10,000 (ISO 7) clean production area. It also houses a 9,000 sq ft well equipped filter validation lab with all the necessary instruments that are required to deal with modern day drug formulations, novel drug delivery systems (NDDS), oncology drugs and therapeutic recombinant proteins.

Products are exported to more than 50 countries worldwide, including US, Western Europe, China and South Korea. The company has deep penetration in the India biopharmaceutical industry and enjoys dominant position in many product segments. An overseas office has recently been set up in California, US and work is on for setting up a new joint venture company in the US.

Advanced Microdevices included nucleic acid isolation, purification, and separation kits in its product range. The company also produces very consistent nitrocellulose membranes for rapid immunodiagnostic tests, whose quality is world renowned. MDI is the global leader in these membranes. The MDI red blood cells (RBC) separator for lateral flow tests is the best in the market in terms of efficacy and efficiency. A unique rapid plasma separation device has been developed for use with quantitative diagnostic analyzers and point of care applications (patent pending). The focus at MDI is on using its membrane technologies as a platform for developing new value added products for use in filtration and separation.
MDI product portfolio boasts of more 15,000 products, manufactured in an ISO 9001:2008 certified production facility and are CE certified. A Drug Master File for the filtration products was submitted to the USFDA in the year 2002.